940 results about "Lipopolysaccharide" patented technology

A continuous method for preparing proteosome-amphiphilic determinant vaccines for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosome-amphiphilic determinant complexes (non-covalent complexes) of the vaccine are formed using diafiltration or ultrafiltration to remove the detergent under non-static conditions. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scale-up. In addition, the process permits the reliable and continuous monitoring of the dializate which enhances the efficiency of the entire process. The time of dialysis for the production of a lot of vaccine is reduced from 7-10 days to less than 72 hours and usually less than 48 or 24 hours. The use of the process optimizes the presence of each antigenic component in the preparation of multivalent vaccines.

It has been found that dendritic cells can be prepared which cannot mature. These cells can provide signal 1 to T cells but cannot provide co-stimulatory signal 2. T cells which are stimulated by the permanently immature dendritic cells therefore anergise, so the dendritic cells are tolerogenic rather than immunogenic. The cells are generally CD40^−ve, CD80^−ve and CD86^−ve, and remain so when stimulated by inflammatory mediators such as lipopolysaccharide. The cells can be prepared conveniently by the culturing adherent embryonic stem cells in the presence of GM-CSF.

The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.

Endotoxin, also known as lipopolysaccharides (LPS), is the major mediator of septic shock due to Gram-negative bacterial infection. Chemically synthesized S3 peptide, derived from Sushi3 domain of Factor C, which is the endotoxin-sensitive serine protease of the limulus coagulation cascade, binds and neutralizes LPS activity. Fluorescent tagged-S3 is shown to detect LPS-containing bacteria. For large-scale production of S3 and to mimic other pathogen-recognizing molecules, tandem multimers of the S3 gene were constructed and expressed in E. coli. Tetramer of S3 for example is shown to display an enhanced inhibitory effect on LPS-induced activities. An affinity matrix based on tetramer of S3 is also shown to be particularly efficient at removing LPS.

A process for preparing the oligose of fucosan sulfate includes such steps as preparing the aqueous solution of fucosan sulfate, adding oxidant chosen from hydrogen peroxide, hypochlorous acid, nitrous acid, or their salts, heating, membrane ultrafilter, vacuum concentrating and freeze drying. Its advantages are high medical effect to protect liver and take care of health, and low cost.

This invention is directed to methods for removing, preferably simultaneously and in one step, multiple impurities form crude culture samples, and, in particular, the removal of media components, protein, nucleic acids, lipids, and lipopolysaccharides to ultralow levels. Preferably the purification process comprises: (1) binding of the target substance containing one or more contaminants to a chromatography matrix; (2) washing the bound target substance with one or more buffers containing a synergistic combination of a lyotropic agent or organic solvent, a detergent, and a salt component; and (3) desorbing the target substance from the chromatography matrix, so that the eluate contains ultra low levels of contaminants. The reduction of impurities that can be achieved is preferably 91-99.9% as compared to the amount of impurities in the target substance before purification. The invention is also directed to the targets products that have been so purified.

The invention relates to the use of IL-15 or active variants thereof and/or IL-15 activity enhancing compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system, such as manipulating viability and/or responsiveness of said memory cells. The IL-15 activity enhancing compound is for example lipopolysaccharide (LPS). The invention further relates to the use of IL-15 inhibiting or eliminating compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system. Such inhibiting or eliminating compounds are for example anti-IL-15 antibodies, anti-IL-15Rα antibodies, fragments of these antibodies, e.g. the Fab or F(ab′)₂ fragment, soluble IL-15Rα, fusion proteins consisting of soluble IL-15Rα, and Fc fragment, compounds, e.g. peptides, binding and/or inhibiting functional IL-15 receptor, IL-15 antisense oligonucleotides.

The invention relates to the production of ganglioside specific antibodies. These antibodies are produced following immunization with lipopolysaccharide antigen of Campylobacter jejuni. The antibodies bind to monosialogangliosides, including GM2 and GM1.

Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipopolysaccharide (LPS) endotoxins released from gram-negative bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds LPS from various bacteria with high affinity, decreasing circulating LPS and neutralizes its deleterious biological effects. Consequently, the provided gelsolin replacement therapy offers a method for the prevention of LPS-induced mortality in the patient.

The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.

The invention discloses application of fructus forsythiae aglycone in preparing a medicament for preventing or treating liver injury or liver failure, and belongs to the medical field. The fructus forsythiae aglycone is a traditional Chinese medicine monomer obtained by extracting from the conventional fructus forsythiae, and is shown to have better treatment effect for the liver injury caused by acetaminopben, the livery injury caused by anti-tumor drug cis-platinum, acute or chronic livery injury caused by carbon tetrachloride, the livery injury caused by D-galactosamine and the liver failure caused by the D-galactosamine and lipopolysaccharide according to an animal test, has effect, which is better than that of fructus forsythiae and fructus forsythiae aglycone, in treating liver injury or liver failure. The fructus forsythiae aglycone is exact in curative effect and low in side effect for treating the liver injury and the liver failure, and has wide medical application prospect.

Compositions comprising a source of alkaline phosphatase that prevent or reduce toxic influx of lipopolysaccharide (LPS) through mucosal layers of a mamalian body cavity and methods of using these compositions for those purposes are disclosed. Such a source of alkaline phosphatase, preferably in a medical food such as infant milk formula, is eaten, drunk or otherwise administered for prophylaxis or treatment of LPS-mediated or LPS-exacerbated disease.

The invention discloses a diterpenoid compound and the preparing method and application thereof. The diterpenoid compound is obtained by using aralia melanocarpa roots as the raw material through extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation. The molecular formula of the diterpenoid compound is C20H30O3. The name of the diterpenoid compound is 14-oxygen-ent-8(9),15-(14-oxo-ent-pimara-8(9),15-diene-19-oic acid). The structural formula is as shown in the specification. According to the preparing method, aralia melanocarpa roots are used as the raw material, and extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation are conducted to generate the diterpenoid compound. The diterpenoid compound can be applied to preparation of anti-inflammatory drugs for prevention and/or treatment. The diterpenoid compound is subjected to in-vitro anti-inflammatory activity testing, and experimental results show a good lipopolysaccharide (LPS) restraining effect and a good effect of inducting pulmonary alveolar macrophages (RAW264.7) to generate NO. A new compound or lead compound with high application value can be provided for the medical industry.

The invention relates to a micro-fluidic agglutinin chip, specifically to a method for preparing and modificating a micro-fluidic chip. The micro-fluidic chip is designed and prepared through a micro electro mechanical technology. Dissolved bacterial cellulose is regenerated in a micro channel to be as a filling material of chip channel columns, and agglutinin is fixed on the filling material surface which is subjected to hydrophilic modification; and according to specific affinity effect of agglutinin to glycosyl, substances containing specific glycosyl on the surface, such as glycoprotein and lipopolysaccharide and the like, are separated. The chip consists of a glass base material, channel graph is etched on the base material by an ultraviolet etching technology, and high-temperature bonding is performed by program temperature control. The chip is provided with an inlet and an outlet of a separation sampling, an inlet and an outlet of the filling material, a bacterial cellulose filled column, a sample micro channel and on-line monitoring points. By taking regenerated bacterial cellulose as the chip filling material, the micro-fluidic agglutinin chip has the main advantages of being excellent in effects of bacterial cellulose, simple in fixing step of agglutinin, convenient to perform spectrum monitor, and substantial in glycosyl separation effect.

Lysine-spermine conjugates with a long-chain aliphatic (C₁₂-C₂₀) substituent at R₁ bind and neutralize bacterial lipopolysaccharides. These compounds reduce lethality in a murine model of lipopolysaccharide-induced shock, and may serve as novel leads for developing novel anti-lipopolysaccharide agents for the therapy of Gram-negative sepsis. These compounds are represented by the formula:

wherein X is O or H, H; R is a hydrophobic C₁₂-C₂₀ chain and Y is -NH₂ or -H; and pharmaceutically acceptable salts thereof and prodrugs thereof.

The invention relates to a fattening pig feed for improving the pork quality. The feed comprises the following components in percentage by weight: 72%-75% of corns, 10%-13% of 46.5% bean pulp, 1%-6% of wheat bran, 3%-7% of tea leaf powder, 1.2%-1.5% of bean oil, 1%-1.4% of stone powder, 1.2%-1.4% of calcium hydrogen phosphate, 0.3%-0.6% of salt, 3%-4% of premix, 0.2%-0.3% of lysine, 0.1%-0.2% of methionine and 0.1%-0.2% of threonine. Compared with the prior art, the feed is prepared by drying branches and leaves cut from tea trees, performing conventional or superfine grinding to prepare the tea leaf powder, and adding the tea leaf powder into the fattening pig feed instead of the bran according to a certain ratio; the prepared feed contains not only special nutritional ingredients such as protein, fat, carbohydrate and the like in the tea leaves but also medicinal ingredients such as caffeine, tea polyphenol, lipopolysaccharide, aromatic compounds and the like, and can effectively promote the growth performance of a fattening pig, enhance the anti-stress capability and improve the quality, flavor and mouth feel of pork.

The invention provides a broad-spectrum nucleic acid aptamer capable of identifying lipopolysaccharides of different Gram-negative bacterium sources. The broad-spectrum nucleic acid aptamer is obtained by directed screening on the basis of the capture-SELEX technology of label-free target molecules and immobilized nucleic acid libraries. A directed screening method of the broad-spectrum nucleic acid aptamer includes: using mouse salmonella typhi lipopolysaccharides as the unique target, using a biotin-avidin effect to fix random oligonucleotide libraries to Fe3O4 magnetic nano particles wrapped by avidin through biotinylated short complementary chains, performing incubation, separation, amplification, digestion single chain preparation, cloning sequencing and the like, adding complete active bacteria of salmonella and escherichia coli to serve as directed molecules to perform directed screening when the libraries are enriched to a certain degree, and one broad-spectrum nucleic acid aptamer capable of identifying four kinds of lipopolysaccharides is obtained through 15 rounds of repeated screening. The nucleic acid aptamer is applicable to the analysis and detection, separation and enriching, toxicity neutralizing and the like of the lipopolysaccharides in aspects of drinking water, food or clinical medicine and the like.